abstract |
Provided are an application of chimeric antigen receptor (CAR)-modified T (CAR T) cells in preparing a drug for treating cancer; the CAR T-cells contain an artificially-introduced costimulatory signal conduction domain and do not contain an artificially-introduced first signal conduction domain. |